This core will provide Projects 1, 2 and 3 as well as the Antibody Core with necessary influenza virus reagents to conduct the proposed research. All three Projects as well as the Antibody Core will greatly benefit from this core's ability to produce a large panel of high quality recombinant influenza virus hemagglutinin and neuraminidase proteins as well as chimeric versions of these molecules. These proteins are functional, correctly folded and glycosylated and will be used in various assays by Project 1. 2 and 3 and as baiting agent by the Antibody Core. Furthermore, the core will produce custom made recombinant viruses that express chimeric hemagglutinin, neuraminidase and chimeric neuraminidase proteins in the influenza A and B virus background. Project 1 will use these viruses for analysis of monoclonal antibodies and for mimicking of preexisting immunity in animal models. Finally, the Reagent Core will supply Projects 1, 2 and 3 as well as the Antibody Core with high titer virus stocks, mouse adapted influenza virus challenge strains and purified virus preparations

Public Health Relevance

The Reagent Core will provide recombinant proteins and viruses that have been developed in the Palese laboratory and are not available from any other source. These reagents are essential for the research conducted in Projects 1. 2 and 3.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109946-01
Application #
8667701
Study Section
Special Emphasis Panel (ZAI1-ZL-I (J1))
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
1
Fiscal Year
2014
Total Cost
$153,742
Indirect Cost
$26,419
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ho, Irvin Y; Bunker, Jeffrey J; Erickson, Steven A et al. (2016) Refined protocol for generating monoclonal antibodies from single human and murine B cells. J Immunol Methods 438:67-70
Chen, Chi-Jene; Ermler, Megan E; Tan, Gene S et al. (2016) Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins. J Virol 90:3789-93
Krammer, Florian (2016) Novel universal influenza virus vaccine approaches. Curr Opin Virol 17:95-103
Nachbagauer, Raffael; Choi, Angela; Izikson, Ruvim et al. (2016) Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio 7:e01996-15
Tan, Gene S; Leon, Paul E; Albrecht, Randy A et al. (2016) Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection. PLoS Pathog 12:e1005578
He, Wenqian; Tan, Gene S; Mullarkey, Caitlin E et al. (2016) Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A 113:11931-11936
Neu, Karlynn E; Henry Dunand, Carole J; Wilson, Patrick C (2016) Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol 42:48-55
DiLillo, David J; Palese, Peter; Wilson, Patrick C et al. (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126:605-10
Henry Dunand, Carole J; Leon, Paul E; Huang, Min et al. (2016) Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe 19:800-13
Hamilton, Jennifer R; Sachs, David; Lim, Jean K et al. (2016) Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity. Proc Natl Acad Sci U S A 113:3861-6

Showing the most recent 10 out of 39 publications